OS Therapies acquires full IP rights to OST-HER2 and two cancer assets for $8M.
Read more
uniQure's AMT-162 gene therapy for SOD1-ALS advances to second cohort after positive safety review.
Read more
Atalanta Therapeutics secures $97M to advance RNAi therapies for KCNT1-related epilepsy and Huntington's Disease to clinical trials.
Read more
Anticoagulants market projected to reach $89.5 billion by 2033, driven by cardiovascular disease prevalence and drug innovations.
Read more
Galderma introduces guidelines for managing facial changes in patients undergoing medication-driven weight loss.
Read more
Takeda appoints Julie Kim as CEO, marking a significant leadership change in June 2026.
Read more
GH Research's GH001 shows significant efficacy in Phase 2b trial for Treatment-Resistant Depression with rapid symptom reduction.
Read more
China Jo-Jo Drugstores restructures to focus on wholesale, enhancing profitability and growth.
Read more
FDA approves SYMBRAVO for acute treatment of Migraine, offering rapid and sustained pain relief with a novel multi-mechanistic approach.
Read more
NICE approves exa-cel gene therapy for severe Sickle Cell Disease, offering potential cure under managed access in NHS England.
Read more
Alterity's ATH434 shows significant efficacy in Phase 2 trial for Multiple System Atrophy, slowing disease progression by up to 48%.
Read more
Augnito partners with Almoosa Health to integrate AI Scribe, enhancing clinical workflows in Saudi Arabia.
Read more
CD39-targeted therapies show promise in oncology and autoimmune diseases, with first approval expected by 2029.
Read more
Orion and Invenra partner to develop bispecific antibody cancer therapeutics using Invenra's B-Body® platform.
Read more
GLP-1 receptor agonists impair taste function, affecting dietary choices and metabolic health, study reveals.
Read more
BioAro's PanOmiQ platform accelerates Whole Genome Sequencing, enhancing precision medicine with AI-driven genomic analysis.
Read more
Butterfly Network announces $75.6 million public offering to fund product development and commercialization.
Read more
FDA approves Ozempic® to reduce kidney disease and cardiovascular death risk in Type 2 Diabetes with Chronic Kidney Disease.
Read more
Kinectrics and Isotopia partner to supply Gadolinium-160, advancing Terbium-161 radiotherapeutics for prostate and neuroendocrine tumors.
Read more
Quibim secures $50M for US expansion, enhancing AI tools for tumor detection in MRI, CT, and PET scans.
Read more
Tempus acquires Ambry Genetics to enhance AI-driven precision medicine solutions for improved patient care.
Read more
Acellera and Psivant partner to enhance drug discovery using AI and quantum simulations for small molecule therapeutics.
Read more
Pfizer's BRAFTOVI regimen improves survival in Phase 3 trial for metastatic colorectal cancer with BRAF V600E mutation.
Read more
FDA approves Journavx, a first-in-class non-opioid analgesic for moderate to severe acute pain in adults.
Read more
March Biosciences' MB-105 CAR-T therapy receives FDA orphan drug status for T-Cell Lymphoma.
Read more
